Alloy Therapeutics, Inc.’s Post

🌟 Honored to see AP Biosciences, Inc. recognized in Labiotech.eu's feature on six bispecific antibody companies shaping the future of oncology and beyond! 🌟 As highlighted in the article, our commitment to advancing bispecific antibody therapies focuses on addressing unmet needs in cancer treatment. With our innovative Omni-mAb and T-cube technologies, we aim to develop next-generation solutions to overcome resistance in solid tumors and enhance the immune response, offering hope to patients worldwide. A heartfelt thank you to Labiotech.eu for spotlighting our work among such distinguished peers. 📖 Read the article here: Six Bispecific Antibody Companies You Should Know 👇️ https://lnkd.in/duhSmFFE 📢 Check out the original post: Labiotech LinkedIn Post #BispecificAntibodies #CancerTreatment #BiotechInnovation #AntibodyTherapies #APBiosciences #Labiotech

Did you know that bispecific antibodies are all the rage at the minute? 💉 Their ability to deliver targeted therapeutics to patients by simultaneously binding to two different antigens or epitopes makes them an extremely attractive proposition to drug developers. 🧬 This can be seen in the fact that there have been multiple deals recently made by big pharma and biotech companies to acquire bispecific antibody companies or assets. 🤝💰 Plus, several biotechs have recently launched specifically to develop these types of drugs. 🚀 Read our latest article to discover six bispecific antibody companies! 👇️ https://lnkd.in/duhSmFFE #bispecificantibodies #drugdevelopment #biotechinnovation #antibodytherapies #biotechstartups  #medicalbreakthroughs   Adaptin Bio, Inc. | Akeso Biopharma | AP Biosciences, Inc. | Candid Therapeutics | Summit Therapeutics, Inc. | Zenas BioPharma

#News: Abzena , a leading end-to-end integrated #CDMO for #complexbiologics and #bioconjugates, has announced the launch of its enhanced #bioassayplatform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of #preclinical #immunogenicity in #protein, #antibody, and #genetherapy therapeutics. The next generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early phase development. Dr Campbell Bunce PhD MBA , CSO of #Abzena said, “Understanding a lead drug candidate’s immunogenicity risk profile and how we can mitigate it is a key step in advancing new drugs from discovery to clinical trials. We developed EpiScreen® 2.0 because we understand that there are many factors that contribute to the immunogenicity risk of a drug, especially with the next-generation therapeutics being developed like Antibody-drug conjugates (ADCs). Read more from Read Magazine 👇🏽 https://lnkd.in/edMsnYXp

6 FREE Webcasts: Antibody Engineering & Therapeutics Spring Digital Week taking place May 20 - 21, 2024 | Join hundreds of your antibody peers 👉 Find out more & secure your free pass here: https://lnkd.in/erFEvh-F From Molecule to Market: Simplifying the Characterization of Antibody-Drug Conjugates (ADCs) 🕘 May 20: 12pm EDT / 5pm BST / 6pm CEST Antibody-drug conjugates (ADCs) are among the fastest growing class of biologics and are developed as a combination of monoclonal antibodies (mAbs) and highly potent cytotoxic molecules (drugs). The antibody, in addition to its own biological specificity through its paratope, has the function of a targeted transporting tool of the drug to the targeted cell. The conjugated molecules or particles typically have cytotoxic activity and thus increase the efficiency of the antibody by an additional mechanism, leading to increased death of cells carrying the target antigen. Conjugation of these drugs to antibodies, however, increases structural complexity, which triggers the need for improved characterization methods. Common analytical technologies for characterization of ADCs, such as liquid chromatography, electrophoresis, and mass spectrometry, are useful in enabling the optimization of ADCs but need to be complemented with technologies that can add biophysical and functional information. This session will demonstrate the use of Octet® Bio-Layer Interferometry (BLI) platform in combination with the iQue® High-Throughput Screening (HTS) by Cytometry to characterize and compare the drug trastuzumab to the trastuzumab-containing reference medicinal products Kadcyla® and Enhertu®. Listeners will learn assay considerations for ADCs characterization and the need for complimentary techniques for selection of optimal drug candidates. 👥 Speaker: David Apiyo, Ph.D., Senior Manager, Application, Sartorius #AntibodyEngineering #Therapeutics #AntibodyDiscovery #AcceleratedDiscovery #DrugConjuates

"The biggest innovations often come from the simplest ideas, and the PD-1/PD-L1 breakthrough is a testament to this principle." PD-1 & PD-L1 users leverage innovative cancer treatments, transforming oncology with immune checkpoint inhibitors. #antibody #cancer biology

This new open access review article is entitled “Generation of binder-format-payload conjugate-matrices by antibody chain-exchange” and looks very interesting to us. The following is the abstract of this paper: “The generation of antibody-drug conjugates with optimal functionality depends on many parameters. These include binder epitope, antibody format, linker composition, conjugation site(s), drug-to-antibody ratio, and conjugation method. The production of matrices that cover all possible parameters is a major challenge in identifying optimal antibody-drug conjugates. To address this bottleneck, we adapted our Format Chain Exchange technology (FORCE), originally established for bispecific antibodies, toward the generation of binder-format-payload matrices (pair-FORCE). Antibody derivatives with exchange-enabled Fc-heterodimers are combined with payload-conjugated Fc donors, and subsequent chain-exchange transfers payloads to antibody derivatives in different formats. The resulting binder-format-conjugate matrices can be generated with cytotoxic payloads, dyes, haptens, and large molecules, resulting in versatile tools for ADC screening campaigns. We show the relevance of pair-FORCE for identifying optimal HER2-targeting antibody-drug conjugates. Analysis of this matrix reveals that the notion of format-defines-function applies not only to bispecific antibodies, but also to antibody-drug conjugates.” The corresponding author of this excellent paper is the prestigious Dr. Ulrich Brinkmann at Roche Pharma Research and Early Development (pRED). Open access to this paper at: https://lnkd.in/eE95n464 Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate

Hot off the press 🔥 A long-awaited Epi-paper was published today in #mAbs! Check out this review of the #ISPRI Toolkit - complete with relevant case studies detailing how crucial conducting preclinical immunogenicity assessments at different stages of development can be to de-risking your biologics pipeline. Want to see ISPRI in action? Join us at the AI / HI & Immunoinformatics Summit in June! https://lnkd.in/eCkHkz8B #bioinformatics #AI #immunogenicity

Ready to start the new year by diving into the powerful possibilities of therapeutic antibodies? In this recent publication by Biocompare, Vector Laboratories' experts Catherine Bladen PhD, VP, Regional Executive, & Principal Advisor, and Pamela James, PhD., VP, Business Operations, share the key considerations developers must consider and how a specialized supplier can help unlock the true therapeutic potential of novel antibody therapies. Read the full article: https://bit.ly/4gZMkjr #ADCs #TherapeuticAntibodies #Biopharma #DrugDevelopment

#Candid will partner with EpimAb Biotherapeutics, #Nona Biosciences and #Ab Studio to boost its pipeline of bispecific antibodies, the company announced in Dec. 16 releases.

2028 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐒𝐡𝐨𝐰 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐚𝐭 $479 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 Download an Illustrative overview: https://lnkd.in/dcKFgHh6 The size of global 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $247.3 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $479.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 14.1% from 2023 to 2028 Market players are increasingly focusing on a collaborative approach with an aim to enhance their market position. This collaborative approach allows players to leverage the research and manufacturing capabilities as well as professional expertise from these organizations thus creating new avenues of growth for market players. For instance, AstraZeneca in collaboration with the University Health Network, 𝐓𝐨𝐫𝐨𝐧𝐭𝐨, has been engaged in a phase II, open-label study to assess the efficacy of AZD2936 in terms of 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 (𝐌𝐑𝐃) 𝐜𝐥𝐞𝐚𝐫𝐚𝐧𝐜𝐞 𝐚𝐧𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐮𝐭𝐜𝐨𝐦𝐞 𝐢𝐧 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐌𝐑𝐃 𝐚𝐟𝐭𝐞𝐫 𝐝𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐯𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐡𝐢𝐠𝐡-𝐫𝐢𝐬𝐤 𝐥𝐨𝐜𝐨𝐫𝐞𝐠𝐢𝐨𝐧𝐚𝐥𝐥𝐲 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐡𝐞𝐚𝐝 𝐚𝐧𝐝 𝐧𝐞𝐜𝐤 𝐬𝐪𝐮𝐚𝐦𝐨𝐮𝐬 𝐜𝐞𝐥𝐥 𝐜𝐚𝐫𝐜𝐢𝐧𝐨𝐦𝐚 (𝐋𝐀-𝐇𝐍𝐒𝐂𝐂) 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Antibody Therapeutics      Chinese Antibody Society      Agenus    Telesis Bio      BigHat Biosciences      Lumen Bioscience      Abpro        Pionyr Immunotherapeutics      Star Therapeutics      Genmab     HARBOUR BIOMED      Zymeworks Inc.      Abilita Therapeutics, Inc.      Prestige Biopharma Group (Prestige Biopharma / Prestige Biologics)      Aethon Therapeutics      Neurimmune AG      Antiverse      RenBio      Apexigen      Yumab GmbH      Humabs BioMed, subsidiary of Vir Biotechnology      DJS Antibodies      Sporos Bioventures      ABL Bio Inc.      Abterra Biosciences      Totient - Part of Absci      Bolden Therapeutics      AAX Biotech AB      Ability Biologics   #𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬𝐌𝐚𝐫𝐤𝐞𝐭